Overview
The intention of research is to establish a multimodal prehabilitation protocol in patients who undergo neoadjuvant chemotherapy prior to gastrectomy, explore the feasibility and effectiveness of the measures and evaluate the effect of program on short-term clinical outcome, fitness and long-term prognosis.
Eligibility
Inclusion Criteria:
- Aged ≥18 years;
- Eastern Cooperative Oncology Group (ECOG) performance status score ≤2;
- Endoscopic biopsies were pathologically confirmed as gastric adenocarcinoma;
- The feasibility of neoadjuvant therapy was suggested by MDT, and the feasibility of radical gastrectomy was re-evaluated after neoadjuvant therapy;
- Blood routine, liver function, kidney function, heart function and lung function were normal before neoadjuvant therapy, and there was no contraindication of chemotherapy and surgery;
- The pregnancy test was negative within 1 month, and she was not pregnant or breastfeeding;
- Informed consent and ability to comply with research protocols.
Exclusion Criteria:
- metastasis;
- End-stage cardiac insufficiency (LVEF<30% or NYHA class IV), liver cirrhosis (Child-Pugh classification C), End-stage renal failure (receives chronic dialysis), or ASA grade IV;
- Cerebral hemorrhage, cerebral infarction, TIA or central nervous system disease or mental illness within 6 months, could not cooperate with the completion of neoadjuvant therapy and pre-rehabilitation exercise;
- Patients have severe infections (such as MODS, etc.) or have allergic reactions to chemotherapy drugs and metabolic disorders;
- Concurrent tumors or other diseases requiring simultaneous surgery (except laparoscopic gallbladder surgery);
- Emergency surgery is required due to tumor complications (e.g., bleeding, perforation, obstruction);
- Patients participating in other clinical trials.